Recent analysis of extensive patient data has quantified the cancer-protective effects of GLP-1 receptor agonists. Women using these medications demonstrated a 17% lower incidence of breast cancer compared to those receiving standard diabetes or obesity treatment. Among patients who developed breast cancer, mortality rates were reduced by 24%. The protective effects emerged after approximately 18 months of continuous treatment, suggesting a time-dependent relationship. This data comes from the largest population study examining cancer outcomes with GLP-1 medications, analyzing 2.3 million women with obesity or type 2 diabetes between 2018 and 2024. The findings represent a significant advancement in understanding how weight-loss and diabetes medications may contribute to cancer risk mitigation beyond their primary metabolic effects.
Was this article helpful?
